The weight loss drugs market size has grown exponentially in recent years. It will grow from $29.92 billion in 2025 to $39.18 billion in 2026 at a compound annual growth rate (CAGR) of 30.9%. The growth in the historic period can be attributed to increasing clinical recognition of obesity as a disease, expansion of pharmaceutical research investments, rising prescription rates for weight management drugs, growing healthcare provider awareness, and availability of FDA-approved therapies.
The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $108.53 billion in 2030 at a compound annual growth rate (CAGR) of 29.0%. The growth in the forecast period can be attributed to increasing demand for next-generation anti-obesity drugs, rising investments in metabolic disorder research, expansion of personalized drug therapies, growing global obesity prevalence, and continuous innovation in drug delivery mechanisms. Major trends in the forecast period include increasing development of GLP-1 and novel drug classes, rising focus on clinically proven weight loss medications, growing adoption of long-acting formulations, expansion of prescription-based obesity treatments, and greater emphasis on regulatory compliance.
The increasing obesity rates are expected to propel the growth of the weight loss drugs market in the coming years. Obesity rate refers to the proportion of individuals in a population who have a body mass index (BMI) equal to or greater than 30. Weight loss drugs are medications used to help individuals with obesity achieve weight loss by reducing appetite, increasing feelings of fullness, or interfering with the absorption of nutrients. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, over 4 billion people are estimated to be obese by 2035. Therefore, the increasing obesity rates are driving the growth of the weight loss drugs market.
Major companies operating in the weight loss drug market are developing innovative products such as Zepbound (tirzepatide) injection to better serve patients. Zepbound is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least 1 weight-related condition. Zepbound has the potential to achieve commercial success as it was the first and only FDA-approved obesity treatment at the time that activates both GIP and GLP-1 receptors.
In December 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche gained access to two obesity drug candidates, including an injectable candidate ready for a phase 2 clinical trial and a daily oral pill candidate in a phase 1 trial. The acquisition aimed to strengthen Roche's position in the competitive and growing obesity drug market. Carmot Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on the discovery and development of disease-modifying therapies for obesity and diabetes.
Major companies operating in the weight loss drugs market are Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG, Bristol Myers Squibb, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline, Takeda Pharmaceutical Company, Eli Lilly and Company, Bayer AG, Amgen Inc., Boehringer Ingelheim group, Novo Nordisk A/S, Merck KGaA, Rhythm Pharmaceuticals Inc., Structure Therapeutics, Viking Therapeutics Inc., Saniona, Zealand Pharma A/S.
North America was the largest region in the Weight Loss Drugs market in 2025. The regions covered in the weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 1-3 business days.
The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $108.53 billion in 2030 at a compound annual growth rate (CAGR) of 29.0%. The growth in the forecast period can be attributed to increasing demand for next-generation anti-obesity drugs, rising investments in metabolic disorder research, expansion of personalized drug therapies, growing global obesity prevalence, and continuous innovation in drug delivery mechanisms. Major trends in the forecast period include increasing development of GLP-1 and novel drug classes, rising focus on clinically proven weight loss medications, growing adoption of long-acting formulations, expansion of prescription-based obesity treatments, and greater emphasis on regulatory compliance.
The increasing obesity rates are expected to propel the growth of the weight loss drugs market in the coming years. Obesity rate refers to the proportion of individuals in a population who have a body mass index (BMI) equal to or greater than 30. Weight loss drugs are medications used to help individuals with obesity achieve weight loss by reducing appetite, increasing feelings of fullness, or interfering with the absorption of nutrients. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, over 4 billion people are estimated to be obese by 2035. Therefore, the increasing obesity rates are driving the growth of the weight loss drugs market.
Major companies operating in the weight loss drug market are developing innovative products such as Zepbound (tirzepatide) injection to better serve patients. Zepbound is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least 1 weight-related condition. Zepbound has the potential to achieve commercial success as it was the first and only FDA-approved obesity treatment at the time that activates both GIP and GLP-1 receptors.
In December 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche gained access to two obesity drug candidates, including an injectable candidate ready for a phase 2 clinical trial and a daily oral pill candidate in a phase 1 trial. The acquisition aimed to strengthen Roche's position in the competitive and growing obesity drug market. Carmot Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on the discovery and development of disease-modifying therapies for obesity and diabetes.
Major companies operating in the weight loss drugs market are Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG, Bristol Myers Squibb, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline, Takeda Pharmaceutical Company, Eli Lilly and Company, Bayer AG, Amgen Inc., Boehringer Ingelheim group, Novo Nordisk A/S, Merck KGaA, Rhythm Pharmaceuticals Inc., Structure Therapeutics, Viking Therapeutics Inc., Saniona, Zealand Pharma A/S.
North America was the largest region in the Weight Loss Drugs market in 2025. The regions covered in the weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Weight Loss Drugs Market Characteristics
3. Weight Loss Drugs Market Supply Chain Analysis
4. Global Weight Loss Drugs Market Trends And Strategies
5. Weight Loss Drugs Market Analysis Of End Use Industries
7. Global Weight Loss Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Weight Loss Drugs Total Addressable Market (TAM) Analysis for the Market
9. Weight Loss Drugs Market Segmentation
10. Weight Loss Drugs Market Regional And Country Analysis
11. Asia-Pacific Weight Loss Drugs Market
12. China Weight Loss Drugs Market
13. India Weight Loss Drugs Market
14. Japan Weight Loss Drugs Market
15. Australia Weight Loss Drugs Market
16. Indonesia Weight Loss Drugs Market
17. South Korea Weight Loss Drugs Market
18. Taiwan Weight Loss Drugs Market
19. South East Asia Weight Loss Drugs Market
20. Western Europe Weight Loss Drugs Market
21. UK Weight Loss Drugs Market
22. Germany Weight Loss Drugs Market
23. France Weight Loss Drugs Market
24. Italy Weight Loss Drugs Market
25. Spain Weight Loss Drugs Market
26. Eastern Europe Weight Loss Drugs Market
27. Russia Weight Loss Drugs Market
28. North America Weight Loss Drugs Market
29. USA Weight Loss Drugs Market
30. Canada Weight Loss Drugs Market
31. South America Weight Loss Drugs Market
32. Brazil Weight Loss Drugs Market
33. Middle East Weight Loss Drugs Market
34. Africa Weight Loss Drugs Market
36. Weight Loss Drugs Market Competitive Landscape And Company Profiles
37. Weight Loss Drugs Market Other Major And Innovative Companies
40. Weight Loss Drugs Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Weight Loss Drugs Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses weight loss drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for weight loss drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The weight loss drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:
1) By Type: Liquid; Tablets; Capsules2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By Application: Weight-Reducing Aid; Fat Absorption Inhibitors; Metabolic Boosters
Subsegments:
1) By Liquid: Syrups; Solutions; Suspensions2) By Tablets: Immediate-Release Tablets; Extended-Release Tablets
3) By Capsules: Hard Capsules; Softgel Capsules
Companies Mentioned: Pfizer Inc. ; Roche ; Merck & Co. ; AbbVie Inc. ; Novartis AG ; Bristol Myers Squibb ; Sanofi S.A. ; AstraZeneca plc ; GlaxoSmithKline ; Takeda Pharmaceutical Company ; Eli Lilly and Company ; Bayer AG ; Amgen Inc. ; Boehringer Ingelheim group ; Novo Nordisk A/S ; Merck KGaA ; Rhythm Pharmaceuticals Inc. ; Structure Therapeutics ; Viking Therapeutics Inc. ; Saniona ; Zealand Pharma A/S
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Pfizer Inc.
- Roche
- Merck & Co.
- AbbVie Inc.
- Novartis AG
- Bristol Myers Squibb
- Sanofi S.A.
- AstraZeneca plc
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Eli Lilly and Company
- Bayer AG
- Amgen Inc.
- Boehringer Ingelheim group
- Novo Nordisk A/S
- Merck KGaA
- Rhythm Pharmaceuticals Inc.
- Structure Therapeutics
- Viking Therapeutics Inc.
- Saniona
- Zealand Pharma A/S
